Cohort1: dose level 1
|
Administration route |
intratympanic injection |
Dosage |
0.1 mg/mL |
Pts |
3 |
Age |
Adult, Older_Adult |
Outcome |
1/3(CR); 2/3(PR) |
Adverse reactions |
ransient pain during the electroporation procedure; bleeding around the treatment site |
References |
PMID:
19029422
|
|
Cohort2: dose level 2
|
Administration route |
intratympanic injection |
Dosage |
0.25 mg/mL |
Pts |
3 |
Age |
Adult, Older_Adult |
Outcome |
1/3(CR); 2/3(PR) |
Adverse reactions |
ransient pain during the electroporation procedure; bleeding around the treatment site |
References |
PMID:
19029422
|
|
Cohort3: dose level 3
|
Administration route |
intratympanic injection |
Dosage |
0.5 mg/mL |
Pts |
3 |
Age |
Adult, Older_Adult |
Outcome |
2/3(CR); 1/3(PR) |
Adverse reactions |
ransient pain during the electroporation procedure; bleeding around the treatment site |
References |
PMID:
19029422
|
|
Cohort4: dose level 4
|
Administration route |
intratympanic injection |
Dosage |
1.0 mg/mL |
Pts |
3 |
Age |
Adult, Older_Adult |
Outcome |
1/3(CR); 2/3(PR) |
Adverse reactions |
ransient pain during the electroporation procedure; bleeding around the treatment site |
References |
PMID:
19029422
|
|
Cohort5: dose level 5
|
Administration route |
intratympanic injection |
Dosage |
1.6 mg/mL |
Pts |
12 |
Age |
Adult, Older_Adult |
Outcome |
9/12(CR); 3/12(PR) |
Adverse reactions |
ransient pain during the electroporation procedure; bleeding around the treatment site |
References |
PMID:
19029422
|
|